VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, Hsieh PA, Wollacott A, Viswanathan K, Adari H, Cho SF, Li Y, Chen H, Yang W, Xu Y, An G, Qiu L, Munshi N, Babcock G, Shriver Z, Myette JR, Anderson KC, Tai YT.
Yu T, et al. Among authors: lin l.
Blood Cancer J. 2020 Nov 2;10(11):110. doi: 10.1038/s41408-020-00378-z.
Blood Cancer J. 2020.
PMID: 33149123
Free PMC article.